ArtVentive Medical Group (OTC:AVTD) announced plans to launch its EOS peripheral vascular endoluminal occlusion system in the European Union following CE Mark approval for the self-expanding catheter device.
The Carlsbad, Calif.-based company touted its newly-approved EOS system as a safe alternative to surgery in some patients. It’s designed for the permanent or reversible occlusion of the lumen body cavity.
"The CE Mark also paves the way to facilitate approvals for the ArtVentive EOS device internationally in meeting with the company’s global mandate," CEO Jim Graham said in prepared remarks.
In March 2011 ArtVentive froze development of the device, saying it would move ahead with commercialization plans, a month after raising $10 million to fund clinical trials of the EOS device.
